View all cases
UPC CFI 505/2023
Jan 10, 2024·EP3536712 · METHODS FOR REDUCING LIPOPROTEIN(A) LEVELS BY ADMINISTERING AN INHIBITOR OF PROPROTEIN CONVERTASE SUBTILISIN KEXIN-9 (PCSK9)
Action number: ACT 597355/2023
- Case details
- StatusCase Closed (No infringement)ActionInfringementCategoryMain infringement action
- Parties
- Claimants
- Sanofi Biotechnology SASOperating co.
- Regeneron Pharmaceuticals Inc.Operating co.
Representatives- Niels Hoelder-Hoffmann Eitle
- Mike Gruber-Hoffmann Eitle
- Michael Pfeifer-Hoffmann Eitle
- Daniel Wise-Carpmaels & Ransford
- Agathe Michel-De Cazotte-Carpmaels & Ransford
Respondents- Amgen Inc.Operating co.
- Amgen Europe B.V.Operating co.
- Amgen NVOperating co.
- Amgen GmbHOperating co.
- Amgen B.V.Operating co.
- Amgen S.A.S.Operating co.
- Amgen S.R.L.Operating co.
Representatives- Johannes Heselberger-Bardehle Pagenberg
- Nadine Westermeyer-Bardehle Pagenberg
- Division
- Dusseldorf LD
- Technology
- ChemistryBiotechnology · Pharmaceuticals
- Language
- English
- First decided
- May 13, 2025
- EPO Opposition
- Amgen Inc.Withdrawn2024-02-29
How this compares
The court's record for this kind of case, counted in first-instance rulings. A figure in brackets is the number of rulings a rate rests on.
| Infringement found | Median days to first decision | |
|---|---|---|
| All UPC | 53% (62/117) | 124 |
| Dusseldorf LD | Locked | Locked |
| Judge Ronny Thomas | Locked | Locked |
| Judge Berenice Thom | Locked | Locked |
| Judge András Kupecz | Locked | Locked |
| Judge Xavier Dorland-Galliot | Locked | Locked |
At the UPC: Sanofi Group (33 cases)·Amgen Group (19 cases)
Start 14-day free trialAlready a user? Sign in
Related cases
All proceedings on this patentThis dispute contains 5 other proceedings
UPC CoA 641/2025·UPC CoA 646/2025·UPC CFI 534/2025·UPC CFI 195/2025·CC 24999/2024
Start a free trial to see how each one ended.
More cases: Dusseldorf LD·2023
Decisions
- 2025-05-13Infringement ActionPublic
Summary: The Düsseldorf Local Division dismissed Sanofi and Regeneron's infringement action and Amgen's counterclaim for revocation concerning EP3536712 (a second medical use patent for evolocumab in paediatric patients), finding no infringement of the second medical use claim and that the counterclaim for revocation was also unfounded, with each side bearing the costs of the proceedings they lost.
Show the legal issues (6)
- Second medical use claims (Art. 54(5) EPC)
- Infringement of second medical use claims
- Novelty of second medical use claims
- Inventive step / obviousness
- Pleading ignorance (inadmissibility)
- Counterclaim for revocation
Documents
| Document title | Date | Public |
|---|---|---|
| Cover sheet | 2025-11-03 | Not public |
| Application document Defendant | 2025-11-03 | Not public |
| Receipt | 2025-11-03 | Not public |
| Receipt | 2025-06-27 | Not public |
| 250623 Request re. Audio Recording | 2025-06-23 | Not public |
| Outcome of the Order | 2025-06-16 | Not public |
| Workflow closed | 2025-06-16 | Public |
| Receipt | 2025-06-13 | Not public |
| 20250613_Application_cost_decision_Amgen | 2025-06-13 | Not public |
| Headnote-and-Keywords | 2025-05-13 | Not public |
| DecisionOutcome | 2025-05-13 | Not public |
| Final decision | 2025-05-13 | Public |
| Outcome of the Order | 2025-04-30 | Not public |
| Confirmation of appointment | 2025-04-30 | Public |
| Receipt | 2025-04-22 | Not public |
| 20250417_Recording_of_oral_hearing_Request_Amgen_en | 2025-04-17 | Not public |
| Reschedule announcement | 2025-04-04 | Public |
| Receipt | 2025-03-03 | Not public |
| 250227 Email re correction | 2025-03-03 | Not public |
| 250214 Order Correction of Claimant's name | 2025-03-03 | Not public |
| Request for correction | 2025-03-03 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S03 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S03 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S04 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S01 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S02 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S02 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S04 | 2025-02-26 | Not public |
| 597355/2023/OH/DUS-LOC/UPC202502250930AM/S01 | 2025-02-26 | Not public |
| Interim-Procedure-Closure | 2025-02-21 | Not public |
| Summon-Oral-Hearing | 2025-02-21 | Not public |
| New upload due to technical reasons | 2025-02-21 | Public |
| Hearing-Dates | 2025-02-21 | Not public |
| Response on requests and synoptical table | 2025-02-21 | Not public |
| Summary of citations | 2025-02-21 | Not public |
| Exhibit BP 85 - Amgen | 2025-02-21 | Not public |
| 20250221_Table_of_Exhibits_and_Request_ARs_Brief_Amgen | 2025-02-21 | Not public |
| Course of the oral hearing | 2025-02-20 | Public |
| Outcome of the Order | 2025-02-20 | Not public |
| Rejecting Time Extension | 2025-02-20 | Public |
| Rectification Order 2025_02_03 | 2025-02-20 | Not public |
| Order Interim Procedure | 2025-02-19 | Public |
| Template-Order | 2025-02-19 | Not public |
| Written-Procedure-Closure | 2025-02-19 | Not public |
| Outcome of the Order | 2025-02-19 | Not public |
| Art. 33 3)(a) UPCA | 2025-02-19 | Public |
| Receipt | 2025-02-19 | Not public |
| Cover letter on submssion of slides | 2025-02-18 | Not public |
| Slides for the hearing on 25 February 2025 | 2025-02-18 | Not public |
| Request on timing of complete statement of claim | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| 20250218_Comment_re_CfR_Amgen_App_5925_2025_en_signed | 2025-02-18 | Not public |
| Receipt | 2025-02-18 | Not public |
| Exhibit_BP84_Amgen | 2025-02-18 | Not public |
| 20250218_Response_Amgen_App_6226_2025 | 2025-02-18 | Not public |
| Outcome of the Order | 2025-02-14 | Not public |
| Decision regarding R.9 request | 2025-02-14 | Public |
| Opportunity to comment | 2025-02-14 | Not public |
| Outcome of the Order | 2025-02-14 | Not public |
| Correction Name | 2025-02-14 | Public |
| Receipt | 2025-02-06 | Not public |
| 3rd Prof. Parhofer declaration | 2025-02-05 | Not public |
| HE 116a | 2025-02-05 | Not public |
| HE 116a | 2025-02-05 | Not public |
| Application pursuant to Rule 9.1 RoP | 2025-02-05 | Not public |
| Receipt | 2025-02-05 | Not public |
| Sanofi v Amgen - Rule 336 RoP - Request to file demonstratives | 2025-02-04 | Not public |
| Rectification | 2025-02-03 | Public |
| Rectification | 2025-02-03 | Public |
| Separation of proceedings | 2025-01-30 | Public |
| Receipt | 2025-01-21 | Not public |
| 250120 Reply to Order on separation and value of action | 2025-01-20 | Not public |
| Receipt | 2025-01-20 | Not public |
| Response_re_separation_of_EP857_and_value_in_litigation | 2025-01-20 | Not public |
| Preliminary_Objection_DecisionOutcome | 2024-12-23 | Not public |
| R. 20.2 RoP Information | 2024-12-23 | Public |
| Hearing-Dates | 2024-12-13 | Not public |
| Order - set date and summon to oral hearing | 2024-12-13 | Public |
| Hearing-Dates | 2024-12-13 | Not public |
| Panel-Appointment | 2024-12-05 | Not public |
| Outcome of the Order | 2024-11-29 | Not public |
| Order Inform PCFI allocation TQJ | 2024-11-29 | Public |
| Receipt | 2024-11-14 | Not public |
| Exhibit BP82_Minutes oral hearing in main damages case | 2024-11-13 | Not public |
| Exhibit BP83_court notice re re-scheduled oral hearing in main damages case | 2024-11-13 | Not public |
| Application to comment re. scheduling - Nov 13 2024 | 2024-11-13 | Not public |
| HE 115 241016 Munich Court order | 2024-11-11 | Not public |
| 241111 Comments | 2024-11-11 | Not public |
| HE 114 Confirmation Ski Rauline (redacted) | 2024-11-11 | Not public |
| HE 115 241016 Munich Court order | 2024-11-11 | Not public |
| HE 114 Confirmation Ski Rauline (redacted) | 2024-11-11 | Not public |
| 241111 Comments | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| 20241111_Request_for_hearing_date_Brief_of_Amgen | 2024-11-11 | Not public |
| Pre-Order Opportunity to comment Oral hearing date | 2024-11-05 | Not public |
| Receipt | 2024-10-21 | Not public |
| EP857 Reply to Amgen response to application for leave to amend case (signed) | 2024-10-18 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Response to application for leave to amend the case R263 | 2024-10-09 | Not public |
| Receipt | 2024-10-09 | Not public |
| 241008 Submission on lis pendens | 2024-10-08 | Not public |
| Receipt | 2024-10-04 | Not public |
| Correction | 2024-10-04 | Not public |
| Receipt | 2024-10-04 | Not public |
| Application | 2024-10-03 | Not public |
| Order Opportunity to comment | 2024-09-26 | Not public |
| Receipt | 2024-09-25 | Not public |
| Exhibit HE 106 | 2024-09-25 | Not public |
| HE 104 Decision to grant | 2024-09-25 | Not public |
| Exhibit HE 108 | 2024-09-25 | Not public |
| HE 107 Confirmatory License Agreement | 2024-09-25 | Not public |
| HE 105 Intention to grant | 2024-09-25 | Not public |
| Exhibit HE 109 | 2024-09-25 | Not public |
| Application to Amend Case | 2024-09-25 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP78 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP77 | 2024-09-23 | Not public |
| Exhibit_BP80 | 2024-09-23 | Not public |
| Exhibit_BP75 | 2024-09-23 | Not public |
| Exhibit_BP76 | 2024-09-23 | Not public |
| Infringement rejoinder and validity reply | 2024-09-23 | Not public |
| Exhibit_BP81 | 2024-09-23 | Not public |
| Exhibit_BP79 | 2024-09-23 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| Reply to defence and defence to counterclaim | 2024-07-22 | Not public |
| Acknowledgement-of-lodging | 2024-07-22 | Not public |
| AR 2 - clean | 2024-07-22 | Not public |
| HE 54 - Form 8-K filing to US SEC April 7 2020 | 2024-07-22 | Not public |
| HE 45 - Amgens reply of 25 April 2024 | 2024-07-22 | Not public |
| HE 74 - Soutar 1991 | 2024-07-22 | Not public |
| HE 59 - Bonny eingetreten im November 2019 - Sanofi Biotechnology SAS (FR) | 2024-07-22 | Not public |
| HE 58 - Confirmation of Power to Act - July 16 2024 | 2024-07-22 | Not public |
| HE 49 - SmPC training presentation of the EMAs SmPC Advisory group | 2024-07-22 | Not public |
| HE 60 - Lippi 2011 | 2024-07-22 | Not public |
| HE 67 - Kochinsky and Marcovina 2009 | 2024-07-22 | Not public |
| HE 99 - Szarek 2020 | 2024-07-22 | Not public |
| HE 80 - Schwartz 2018 | 2024-07-22 | Not public |
| HE 101 SmPC for Repatha (2015) | 2024-07-22 | Not public |
| HE 62 - Tregouet 2009 | 2024-07-22 | Not public |
| HE 83 - Albers 2013 (AIM-HIGH) | 2024-07-22 | Not public |
| HE 57a - EN | 2024-07-22 | Not public |
| HE 78 - Cohen 2006 | 2024-07-22 | Not public |
| HE 57 - Laurent Gilhodes as chairman of Sanofi Biotechnologies SAS (FR) | 2024-07-22 | Not public |
| HE 97 Declaration of Prof Di Angelantonio | 2024-07-22 | Not public |
| AR 5a - tracked | 2024-07-22 | Not public |
| AR 5 - clean | 2024-07-22 | Not public |
| HE 75 - Schmidt 2016 | 2024-07-22 | Not public |
| HE 45a - EN | 2024-07-22 | Not public |
| HE 46a - O Donoghue et al supplemental material | 2024-07-22 | Not public |
| AR 1 - clean | 2024-07-22 | Not public |
| HE 50 - Statement of defence (DE) | 2024-07-22 | Not public |
| HE 85 - Romangnuolo 2015 | 2024-07-22 | Not public |
| AR 1a - tracked | 2024-07-22 | Not public |
| HE 47a - EN | 2024-07-22 | Not public |
| HE 46 - O Donoghue et al circulation | 2024-07-22 | Not public |
| HE 40b - Verification of electronic signatures for HE 40 | 2024-07-22 | Not public |
| HE 51a - Report from the CMDh meeting held on 16th 17th and 18th January 2012 | 2024-07-22 | Not public |
| HE 68 - Koschinsky and Boffa 2014 | 2024-07-22 | Not public |
| HE 52 -SmPC Atorvastatin (DE) | 2024-07-22 | Not public |
| AR 3 - clean | 2024-07-22 | Not public |
| HE 61 - Davignon 2010 | 2024-07-22 | Not public |
| HE 89 - Praluent FDA approval | 2024-07-22 | Not public |
| HE 48 - C Ronse | 2024-07-22 | Not public |
| HE 98 - Safarova 2013 | 2024-07-22 | Not public |
| AR 1b - amended description | 2024-07-22 | Not public |
| HE 93 - Excerpt from clinicaltrials gov - GAUSS | 2024-07-22 | Not public |
| HE 72 - Anuurad 2006 | 2024-07-22 | Not public |
| AR 3a - tracked | 2024-07-22 | Not public |
| HE 82 - Willeit 2018 | 2024-07-22 | Not public |
| HE 77 - Colhoun 2003 | 2024-07-22 | Not public |
| HE 91 - NCT012884443 2011 | 2024-07-22 | Not public |
| HE 51 - CHMP 2012 | 2024-07-22 | Not public |
| HE 73 - Lamon Fava 2014 | 2024-07-22 | Not public |
| HE 81 - Sabatine 2017 | 2024-07-22 | Not public |
| HE 76 - Lambert 2017 | 2024-07-22 | Not public |
| HE 69 - Kolski 2012 | 2024-07-22 | Not public |
| HE 64 - Clarke 2009 | 2024-07-22 | Not public |
| HE 38a - Verification of electronic signatures for HE 38 | 2024-07-22 | Not public |
| HE 95 - Lagor and Millar 2009 | 2024-07-22 | Not public |
| HE 47 - Paris 20 Ocober 2023 1913662 (FR) | 2024-07-22 | Not public |
| HE 55 - PoA executed by Gilhodes (FR) | 2024-07-22 | Not public |
| HE 71 - Rader 1995 | 2024-07-22 | Not public |
| HE 103 - Stein 2009 | 2024-07-22 | Not public |
| HE 53 - 2nd Parhofer declaration Infringment | 2024-07-22 | Not public |
| HE 100 - Summary of pre-priority clinical trials using anti-PCSK9 antibodies | 2024-07-22 | Not public |
| AR 2a - tracked | 2024-07-22 | Not public |
| HE 63 - Kamstrup 2009 | 2024-07-22 | Not public |
| AR 3b - amended description | 2024-07-22 | Not public |
| HE 96 - Swergold poster | 2024-07-22 | Not public |
| HE 94 - Excerpt from clinicaltrials gov - AMG145 | 2024-07-22 | Not public |
| HE 58a - Coury Witness Statement 18 July 2024 | 2024-07-22 | Not public |
| HE 88 - Kamstrup 2008 | 2024-07-22 | Not public |
| AR 4b - amended description | 2024-07-22 | Not public |
| HE 86 - Cohen 2005 | 2024-07-22 | Not public |
| HE 84 - Stroes 2016 | 2024-07-22 | Not public |
| HE 87 - JAMA 2009 | 2024-07-22 | Not public |
| HE 92 Declaration of Prof Parhofer on validity | 2024-07-22 | Not public |
| HE 65 - Dube 2012 | 2024-07-22 | Not public |
| HE 90 - Repatha FDA approval | 2024-07-22 | Not public |
| HE 66 - Jacobson 2013 | 2024-07-22 | Not public |
| AR 4a - tracked | 2024-07-22 | Not public |
| AR 2b - amended description | 2024-07-22 | Not public |
| HE 56 - Second Confirmatory License Agreement | 2024-07-22 | Not public |
| HE 102 - SmPC for Praluent (2015) | 2024-07-22 | Not public |
| Reply to Defence and Defence to Counterclaim | 2024-07-22 | Not public |
| HE 70 - Hobbs 1999 | 2024-07-22 | Not public |
| HE 55a - EN | 2024-07-22 | Not public |
| AR 4 - clean | 2024-07-22 | Not public |
| HE 50a - EN | 2024-07-22 | Not public |
| HE 79 - Ober 2009 | 2024-07-22 | Not public |
| HE 59a - EN | 2024-07-22 | Not public |
| AR 5b - amended description | 2024-07-22 | Not public |
| Outcome of the Order | 2024-07-01 | Not public |
| 2024-07-01 Procedural Order Extension time limit | 2024-07-01 | Public |
| Response_on_time_extension_request_from_Sanofi | 2024-07-01 | Not public |
| Opportunity to comment | 2024-06-26 | Not public |
| Receipt | 2024-06-26 | Not public |
| 2024.06.25 - Request for an extension | 2024-06-25 | Not public |
| Exhibit_BP74 | 2024-06-20 | Not public |
| Fruther_brief_re_preliminary_objection_EN | 2024-06-20 | Not public |
| 240517 Notice re preliminary objection_sgn | 2024-06-18 | Not public |
| HE 43a - Translation HE 43 | 2024-06-18 | Not public |
| HE 44a - Translation HE 44 | 2024-06-18 | Not public |
| HE 43 - RC Dusseldorf Order of 13 May 2024 | 2024-06-18 | Not public |
| HE 44 - RC Dusseldorf Order of 3 May 2024 | 2024-06-18 | Not public |
| Case Management Preliminary Objection | 2024-06-17 | Not public |
| Receipt | 2024-05-21 | Not public |
| Request to Produce Evidence | 2024-05-21 | Not public |
| Request to Produce Evidence | 2024-05-21 | Not public |
| Request to Produce Evidence | 2024-05-21 | Not public |
| Receipt | 2024-05-17 | Not public |
| HE 44 | 2024-05-17 | Not public |
| HE 43a | 2024-05-17 | Not public |
| HE 44a | 2024-05-17 | Not public |
| Notice re PO | 2024-05-17 | Not public |
| HE 43 | 2024-05-17 | Not public |
| Notice re PO | 2024-05-17 | Not public |
| HE 44 | 2024-05-17 | Not public |
| HE 43a | 2024-05-17 | Not public |
| HE 44a | 2024-05-17 | Not public |
| HE 43 | 2024-05-17 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-05-06 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Statement_of_defense_and_Counterclaim_for_Revocation_Amgen_May_3_2024_en signed | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Statement_of_defense_and_Counterclaim_for_Revocation_Amgen_May_3_2024_en signed | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Statement_of_defense_and_Counterclaim_for_Revocation_Amgen_May_3_2024_en signed | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit BP14 | 2024-05-03 | Not public |
| Exhibit BP8 | 2024-05-03 | Not public |
| Exhibit BP73 | 2024-05-03 | Not public |
| Exhibit BP54 | 2024-05-03 | Not public |
| Exhibit BP22 | 2024-05-03 | Not public |
| Exhibit BP5 | 2024-05-03 | Not public |
| Exhibit BP46 | 2024-05-03 | Not public |
| Exhibit BP28 | 2024-05-03 | Not public |
| Exhibit BP6 Part 4 | 2024-05-03 | Not public |
| Exhibit BP69a | 2024-05-03 | Not public |
| Exhibit BP31 | 2024-05-03 | Not public |
| Exhibit BP10 | 2024-05-03 | Not public |
| Exhibit BP26 | 2024-05-03 | Not public |
| Exhibit BP70 | 2024-05-03 | Not public |
| Exhibit BP52a | 2024-05-03 | Not public |
| Exhibit BP33 | 2024-05-03 | Not public |
| Exhibit BP72 | 2024-05-03 | Not public |
| Exhibit BP11 | 2024-05-03 | Not public |
| Exhibit BP42 | 2024-05-03 | Not public |
| Exhibit BP9 | 2024-05-03 | Not public |
| Exhibit BP55 | 2024-05-03 | Not public |
| Exhibit BP7 | 2024-05-03 | Not public |
| Exhibit BP23 | 2024-05-03 | Not public |
| Exhibit BP49a | 2024-05-03 | Not public |
| Exhibit BP12 | 2024-05-03 | Not public |
| Exhibit BP64a | 2024-05-03 | Not public |
| Exhibit BP53a | 2024-05-03 | Not public |
| Exhibit BP18 | 2024-05-03 | Not public |
| Exhibit BP40 | 2024-05-03 | Not public |
| Exhibit BP27 | 2024-05-03 | Not public |
| Exhibit BP49 | 2024-05-03 | Not public |
| Exhibit BP57 | 2024-05-03 | Not public |
| Exhibit BP56 Part 1 | 2024-05-03 | Not public |
| Exhibit BP63a | 2024-05-03 | Not public |
| Exhibit BP30 | 2024-05-03 | Not public |
| Exhibit BP47 | 2024-05-03 | Not public |
| Exhibit BP19 | 2024-05-03 | Not public |
| Exhibit BP47a | 2024-05-03 | Not public |
| Exhibit BP37 | 2024-05-03 | Not public |
| Exhibit BP24 | 2024-05-03 | Not public |
| Exhibit BP43 | 2024-05-03 | Not public |
| Exhibit BP66a | 2024-05-03 | Not public |
| Exhibit BP45 | 2024-05-03 | Not public |
| Exhibit BP21 | 2024-05-03 | Not public |
| Exhibit BP48a | 2024-05-03 | Not public |
| Exhibit BP65 | 2024-05-03 | Not public |
| Exhibit BP41 | 2024-05-03 | Not public |
| Exhibit BP13 | 2024-05-03 | Not public |
| Exhibit BP61 | 2024-05-03 | Not public |
| Exhibit BP16 | 2024-05-03 | Not public |
| Exhibit BP32 | 2024-05-03 | Not public |
| Exhibit BP56 Part 2 | 2024-05-03 | Not public |
| Exhibit BP6 Part 3 | 2024-05-03 | Not public |
| Exhibit BP29 | 2024-05-03 | Not public |
| Exhibit BP66 | 2024-05-03 | Not public |
| Exhibit BP59 | 2024-05-03 | Not public |
| Exhibit BP44 | 2024-05-03 | Not public |
| Exhibit BP48 | 2024-05-03 | Not public |
| Exhibit BP6 Part 1 | 2024-05-03 | Not public |
| Exhibit BP56a | 2024-05-03 | Not public |
| Exhibit BP50 | 2024-05-03 | Not public |
| Exhibit BP69 | 2024-05-03 | Not public |
| Exhibit BP58 | 2024-05-03 | Not public |
| Exhibit BP67a | 2024-05-03 | Not public |
| Exhibit BP71 | 2024-05-03 | Not public |
| Exhibit BP64 | 2024-05-03 | Not public |
| Exhibit BP53 | 2024-05-03 | Not public |
| Exhibit BP20 | 2024-05-03 | Not public |
| Statement of defense | 2024-05-03 | Not public |
| Exhibit BP35 | 2024-05-03 | Not public |
| Exhibit BP39 | 2024-05-03 | Not public |
| Exhibit BP17 | 2024-05-03 | Not public |
| Exhibit BP33a | 2024-05-03 | Not public |
| Exhibit BP38 | 2024-05-03 | Not public |
| Exhibit BP68a | 2024-05-03 | Not public |
| Exhibit BP52 | 2024-05-03 | Not public |
| Exhibit BP60 | 2024-05-03 | Not public |
| Exhibit BP46a | 2024-05-03 | Not public |
| Exhibit BP15 | 2024-05-03 | Not public |
| Exhibit BP51a | 2024-05-03 | Not public |
| Exhibit BP63 | 2024-05-03 | Not public |
| Exhibit BP70a | 2024-05-03 | Not public |
| Exhibit BP50a | 2024-05-03 | Not public |
| Exhibit BP36 | 2024-05-03 | Not public |
| Exhibit BP6 Part 2 | 2024-05-03 | Not public |
| Exhibit BP34 | 2024-05-03 | Not public |
| Exhibit BP68 | 2024-05-03 | Not public |
| Exhibit BP25 | 2024-05-03 | Not public |
| Exhibit BP62 | 2024-05-03 | Not public |
| Exhibit BP51 | 2024-05-03 | Not public |
| Exhibit BP67 | 2024-05-03 | Not public |
| Exhibit BP34a | 2024-05-03 | Not public |
| Exhibit BP60a | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Statement_of_defense_and_Counterclaim_for_Revocation_Amgen_May_3_2024_en signed | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Statement_of_defense_and_Counterclaim_for_Revocation_Amgen_May_3_2024_en signed | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Acknowledgement-of-lodging | 2024-05-03 | Not public |
| Exhibit_BP24_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP67_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP48_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP13_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP10_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP22_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP15_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP09_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP70a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP14_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP21_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP42_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP57_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49_Amgen_fr | 2024-05-03 | Not public |
| Exhibit_BP59_Amgen_en | 2024-05-03 | Not public |
| Statement of defense | 2024-05-03 | Not public |
| Exhibit_BP64_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP07_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP54_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP25_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP62_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP35_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP27_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP18_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_2_fr | 2024-05-03 | Not public |
| Exhibit_BP43_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP17_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP32_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP41_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP73_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_4_en | 2024-05-03 | Not public |
| Exhibit_BP70_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP36_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP58_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP05_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP08_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP51_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP46_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP64a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_3_en | 2024-05-03 | Not public |
| Exhibit_BP40_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP46a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP66_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP48a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP56_Amgen_Part_1_fr | 2024-05-03 | Not public |
| Exhibit_BP37_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP26_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP29_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_2_en | 2024-05-03 | Not public |
| Exhibit_BP69a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP71_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP28_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP52a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP33_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP67a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP19_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP68_Amgen_it | 2024-05-03 | Not public |
| Exhibit_BP61_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP68a-Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP63a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP69_Amgen_be | 2024-05-03 | Not public |
| Exhibit_BP23_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP47_Amgen_nl | 2024-05-03 | Not public |
| Exhibit_BP06_Amgen_Part_1_en | 2024-05-03 | Not public |
| Exhibit_BP65_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP33a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP66a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP45_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP12_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP72_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP55_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP44_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP50a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP20_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP11_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP49a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP16_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP34a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP60a_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP39_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP38_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP53_Amgen_de | 2024-05-03 | Not public |
| Exhibit_BP30_Amgen_en | 2024-05-03 | Not public |
| Exhibit_BP31_Amgen_en | 2024-05-03 | Not public |
| commentPreliminaryObjection | 2024-03-18 | Not public |
| Response to Preliminary Objection | 2024-03-18 | Not public |
| Federal Patent Court, Summons and Preliminary Opinion in accordance with Sec. 83 German Patent Act | 2024-03-18 | Not public |
| Federal Patent Court, Summons and Preliminary Opinion in accordance with Sec. 83 German Patent Act | 2024-03-18 | Not public |
| preliminaryObjection | 2024-03-04 | Not public |
| Exhibit BP03 | 2024-03-04 | Not public |
| Preliminary Objection | 2024-03-04 | Not public |
| Exhibit BP04 | 2024-03-04 | Not public |
| Exhibit BP02a | 2024-03-04 | Not public |
| Exhibit BP02 | 2024-03-04 | Not public |
| Exhibit BP01 | 2024-03-04 | Not public |
| Exhibit BP01a | 2024-03-04 | Not public |
| Exhibit BP03a | 2024-03-04 | Not public |
| Exhibit BP04a | 2024-03-04 | Not public |
| epoUploadDocumentsWorkflow | 2024-02-09 | Not public |
| Document from EPO | 2024-02-09 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Acknowledgement of access to case | 2024-02-05 | Not public |
| Notification Of Service | 2024-02-05 | Not public |
| Panel-Appointment | 2024-01-25 | Not public |
| EPO-Request-for-case-pending | 2024-01-25 | Not public |
| Receipt | 2024-01-25 | Not public |
| Formal-checks_Notification-of-positive-outcome | 2024-01-25 | Not public |
| Acknowledgement-of-lodging | 2024-01-10 | Not public |
| HE 27 - EMA’s Guideline on Summary of Product Characteristics (SmPC) of September 2009 | 2024-01-10 | Not public |
| HE 2 - Printouts from patent register [bundle] | 2024-01-10 | Not public |
| HE 25 - Higher Regional Court of Dusseldorf, GRUR 2019, 279 – Fulvestrant | 2024-01-10 | Not public |
| HE 29 - CMDh Questions & Answers on Usage Patents, CMDh/279/2012, Rev. 1, May 2019 | 2024-01-10 | Not public |
| HE 3 - EP 2 756 004 B1 | 2024-01-10 | Not public |
| HE 20 - F. Kronenberg et al., European Heart Journal (2022) 43, 3925–3946 | 2024-01-10 | Not public |
| HE 38 - Confirmatory License Agreement | 2024-01-10 | Not public |
| HE 11 - Grounds for Defence to Nullity Action dated 15 November 2023 | 2024-01-10 | Not public |
| HE 4 - Notice on the outcome of the opposition on EP’004 of 8/9 June 2022 | 2024-01-10 | Not public |
| HE 9 - Amgen’s submissions on infringement of EP’004 before the RC Dusseldorf (bundle) | 2024-01-10 | Not public |
| HE 6 - Board of Appeal (T1927/22-3.3.04), Preliminary opinion on EP’004 of 6 October 2023 | 2024-01-10 | Not public |
| HE 5 - Opposition Division, Grounds for the decision on EP’004 of 16 August 2022 | 2024-01-10 | Not public |
| HE 26 - Hoge Raad, Judgement of 3 November 2017, 15/04934, ECLI:NL:HR:2017:2807 | 2024-01-10 | Not public |
| HE 35 - Press release of Defendant 1) of 21. July 2015 | 2024-01-10 | Not public |
| HE 12 - Nordestgaard et al, European Heart Journal, 31, 2844-2853, 2010 | 2024-01-10 | Not public |
| HE 36 - Press release of Defendant 1) of 21. February 2017 | 2024-01-10 | Not public |
| HE 30 - EMA, CHMP, Assessment report Repatha®, EMA/CHMP/222019/2015 (excerpt) | 2024-01-10 | Not public |
| HE 31 - EMA, CHMP, CHMP day 120 list of questions, Evolocumab Amgen Europe B.V., EMA/CHMP/33068/2015 (excerpt) | 2024-01-10 | Not public |
| HE 41 - Appointment Alban De La Sablière | 2024-01-10 | Not public |
| HE 26a - English translation (EN) | 2024-01-10 | Not public |
| HE 17 - Feature Analysis Patent in Suit | 2024-01-10 | Not public |
| HE 19 - Wilson et al., Journal of Clinical Lipidology (2019) 13, 374–392 | 2024-01-10 | Not public |
| HE 28 - Case T452/14, Laboratoires CTRS v European Commission, ECLI:EU:T:2015:373 | 2024-01-10 | Not public |
| HE 8 - Claimants’ submissions on infringement of EP’004 before the RC Dusseldorf (bundle) | 2024-01-10 | Not public |
| HE 10 - Amgen’s Nullity Action on EP’004 dated 3 August 2023 filed before the Federal Patent Court (3 Ni 21/23) | 2024-01-10 | Not public |
| HE 34 - EP 2 215 124 B9 (excerpt) | 2024-01-10 | Not public |
| HE 15 - Bennet et al, Arch Intern Med, Vol. 168, No. 6, 2008; | 2024-01-10 | Not public |
| HE 22 - Website https://fachkreise.amgen.de/Produkte/Repatha/index.html | 2024-01-10 | Not public |
| 240110 Statement of Claim_sig | 2024-01-10 | Not public |
| HE 13 - Horton et al., 2009 | 2024-01-10 | Not public |
| HE 40 - Power of Attorney John C. Conway (French) | 2024-01-10 | Not public |
| HE 21 - Expert declaration Prof. Klaus G. Parhofer | 2024-01-10 | Not public |
| HE 7 - Board of Appeal (T1927/22-3.3.04), Minutes of the hearing on 6 December 2023 | 2024-01-10 | Not public |
| HE 40a - Translation HE 40 (EN) | 2024-01-10 | Not public |
| HE 16 - JAMA. 2009;302(4):412-423. doi:10.1001/jama.2009.1063 (including online supplement) | 2024-01-10 | Not public |
| HE 14 - Expert Report I by Emanuele Di Angelantonio from the European opposition proceedings (D64) | 2024-01-10 | Not public |
| HE 18 - V Bermudez et. al, American Journal of Therapeutics 17, 263-273 (2 | 2024-01-10 | Not public |
| HE 23 - SmPC of Repatha® | 2024-01-10 | Not public |
| HE 33 - Amgen Inc., Annual Report (10-K Filing) for fiscal year ended December 31, 2020 (excerpt) | 2024-01-10 | Not public |
| HE 37 - Lauer-Taxe excerpt | 2024-01-10 | Not public |
| HE 1 - EP 3 536 712 B1 | 2024-01-10 | Not public |
| HE 39 - Appointment Larry Coury – Secretary Certificate | 2024-01-10 | Not public |
| HE 32 - Parhofer KG et al, Drugs - Real World Outcomes 2019; 6: 115-123 | 2024-01-10 | Not public |
| HE 24 - Fachinformationen Repatha® | 2024-01-10 | Not public |
| HE 25a - Machine translation (EN) | 2024-01-10 | Not public |
| Proof of payment | 2024-01-10 | Not public |
Coverage: Partial.Reasoning extracted with partial coverage — some sections may be incomplete.
Plain-English summary
Sanofi Biotechnologies and Regeneron Pharmaceuticals brought an infringement action against Amgen before the Düsseldorf Local Division concerning EP 3 536 712 B1, a second medical use patent claiming administration of the PCSK9 inhibitor evolocumab to reduce lipoprotein(a) levels in paediatric patients. The court dismissed the infringement action, finding that Amgen did not offer or place evolocumab on the market in a manner that led or could lead to the patented paediatric use; it also dismissed Amgen's revocation counterclaim, finding the patent not invalid. Costs were split, with claimants bearing infringement action costs and defendants bearing revocation counterclaim costs.
Accepted arguments
What the court agreed with — by party.
Second medical use claim of EP 3 536 712 B1 requires that the alleged infringer offer or place the product on the market in a way that leads or may lead to the claimed therapeutic use, and this condition was not met for evolocumab in paediatric patients
RespondentLegal basis: Art. 54(4)(5) EPC; Art. 53(c) EPCNote: Court accepted Amgen's position that the second medical use claim was not infringed because Amgen did not offer evolocumab for the patented paediatric indication in the manner required.
Inventive step of the second medical use claim may be negatived where the skilled person faces many uncertainties or expected difficulties, negating any motivation to implement the claimed use
RespondentLegal basis: Inventive step / obviousness under EPCNote: Court articulated the principle that absence or negation of motivation prevents a finding of obviousness; applied in the counterclaim context.
Pleading ignorance (i.e., inability to admit or deny facts due to lack of knowledge) is inadmissible in UPC proceedings
ClaimantLegal basis: UPC Rules of ProcedureNote: Court held that RoP do not acknowledge pleading ignorance, supporting claimant's position that such objections are disregarded.
Rejected arguments
What the court did not agree with — and why.
Infringement of the second medical use claim of EP 3 536 712 B1 by Amgen's evolocumab product in paediatric patients
ClaimantLegal basis: Art. 54(4)(5) EPC; Art. 53(c) EPCReason: Sanofi/Regeneron failed to establish that Amgen offered or placed evolocumab on the market in a way that leads or may lead to the patented therapeutic use in paediatric patients; all relevant facts and circumstances did not support infringement of the second medical use claim.
Counterclaim for revocation of EP 3 536 712 B1
RespondentReason: Dismissed; patent held not invalid (specific grounds not detailed in the available excerpt).
Key legal principles
Doctrines and rules cited in the reasoning.
Second medical use claims — infringement requires that the alleged infringer offers or places the product on the market in a way that leads or may lead to the claimed therapeutic useSecond medical use claims — notional novelty under Art. 54(5) EPC requires a specific use in a method under Art. 53(c) EPCInventive step — motivation to implement the claimed use may be absent or negated where many uncertainties existPleading ignorance is inadmissible in UPC proceedingsPurposive claim construction — scope of second medical use claim
Browse other cases on this principle.
Claim construction notes
The court interpreted the second medical use claim of EP 3 536 712 B1 as requiring a specific therapeutic use — administration of a PCSK9 inhibitor (evolocumab) to reduce Lp(a) levels in paediatric patients — and held that the requirement of such behaviour cannot be defined abstractly but requires analysis of all relevant facts and circumstances of the specific patent claim.